195 related articles for article (PubMed ID: 19837916)
1. RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact.
Volante M; Rapa I; Gandhi M; Bussolati G; Giachino D; Papotti M; Nikiforov YE
J Clin Endocrinol Metab; 2009 Dec; 94(12):4735-41. PubMed ID: 19837916
[TBL] [Abstract][Full Text] [Related]
2. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
[TBL] [Abstract][Full Text] [Related]
3. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma.
Castro P; Rebocho AP; Soares RJ; Magalhães J; Roque L; Trovisco V; Vieira de Castro I; Cardoso-de-Oliveira M; Fonseca E; Soares P; Sobrinho-Simões M
J Clin Endocrinol Metab; 2006 Jan; 91(1):213-20. PubMed ID: 16219715
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
[TBL] [Abstract][Full Text] [Related]
5. Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant.
Di Cristofaro J; Marcy M; Vasko V; Sebag F; Fakhry N; Wynford-Thomas D; De Micco C
Hum Pathol; 2006 Jul; 37(7):824-30. PubMed ID: 16784981
[TBL] [Abstract][Full Text] [Related]
6. Aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours.
Banito A; Pinto AE; Espadinha C; Marques AR; Leite V
Clin Endocrinol (Oxf); 2007 Nov; 67(5):706-11. PubMed ID: 17651453
[TBL] [Abstract][Full Text] [Related]
7. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations.
Zhu Z; Gandhi M; Nikiforova MN; Fischer AH; Nikiforov YE
Am J Clin Pathol; 2003 Jul; 120(1):71-7. PubMed ID: 12866375
[TBL] [Abstract][Full Text] [Related]
8. N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression.
Basolo F; Pisaturo F; Pollina LE; Fontanini G; Elisei R; Molinaro E; Iacconi P; Miccoli P; Pacini F
Thyroid; 2000 Jan; 10(1):19-23. PubMed ID: 10691309
[TBL] [Abstract][Full Text] [Related]
9. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
10. Mutation profile of differentiated thyroid tumours in an Australian urban population.
Mond M; Alexiadis M; Fuller PJ; Gilfillan C
Intern Med J; 2014 Aug; 44(8):727-34. PubMed ID: 24862939
[TBL] [Abstract][Full Text] [Related]
11. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns.
Rivera M; Ricarte-Filho J; Knauf J; Shaha A; Tuttle M; Fagin JA; Ghossein RA
Mod Pathol; 2010 Sep; 23(9):1191-200. PubMed ID: 20526288
[TBL] [Abstract][Full Text] [Related]
12. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.
Garcia-Rostan G; Zhao H; Camp RL; Pollan M; Herrero A; Pardo J; Wu R; Carcangiu ML; Costa J; Tallini G
J Clin Oncol; 2003 Sep; 21(17):3226-35. PubMed ID: 12947056
[TBL] [Abstract][Full Text] [Related]
13. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.
Nikiforova MN; Lynch RA; Biddinger PW; Alexander EK; Dorn GW; Tallini G; Kroll TG; Nikiforov YE
J Clin Endocrinol Metab; 2003 May; 88(5):2318-26. PubMed ID: 12727991
[TBL] [Abstract][Full Text] [Related]
14. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas.
Nikiforov YE
Endocr Pathol; 2004; 15(4):319-27. PubMed ID: 15681856
[TBL] [Abstract][Full Text] [Related]
15. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.
Moura MM; Cavaco BM; Pinto AE; Leite V
J Clin Endocrinol Metab; 2011 May; 96(5):E863-8. PubMed ID: 21325462
[TBL] [Abstract][Full Text] [Related]
16. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
17. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis.
Giordano TJ; Kuick R; Thomas DG; Misek DE; Vinco M; Sanders D; Zhu Z; Ciampi R; Roh M; Shedden K; Gauger P; Doherty G; Thompson NW; Hanash S; Koenig RJ; Nikiforov YE
Oncogene; 2005 Oct; 24(44):6646-56. PubMed ID: 16007166
[TBL] [Abstract][Full Text] [Related]
18. Genetic Alterations in Differentiated Thyroid Cancer Patients with Acromegaly.
Aydin K; Aydin C; Dagdelen S; Tezel GG; Erbas T
Exp Clin Endocrinol Diabetes; 2016 Mar; 124(3):198-202. PubMed ID: 26575115
[TBL] [Abstract][Full Text] [Related]
19. Molecular testing for oncogenic gene mutations in thyroid lesions: a case-control validation study in 413 postsurgical specimens.
Giordano TJ; Beaudenon-Huibregtse S; Shinde R; Langfield L; Vinco M; Laosinchai-Wolf W; Labourier E
Hum Pathol; 2014 Jul; 45(7):1339-47. PubMed ID: 24830619
[TBL] [Abstract][Full Text] [Related]
20. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
